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Figure 1. Changes in subchondral bone density from baseline at one and two
years after ankle distraction for individual patients.
chondral bone density that persisted for at least two years of
follow-up. This could lead to a more physiologically normal distribu-
tion of mechanical stresses by the less dense bone, encouraging
cartilage repair activity. As such, these prolonged bone changes
may in part explain the clinical beneﬁts of joint distraction.
This study was ﬁnancially supported by grants from the NIH/
NIAMS (AR048939 and AR055533).
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Purpose: The proteinase-activated receptor-2 (PAR-2), member
of the G protein coupled receptor family, was demonstrated to
be implicated in human osteoarthritis (OA) cartilage catabolism
and subchondral bone remodeling.To validate the results of these
in vitro studies, we investigated the in vivo role of PAR-2 in the
development of cartilage and subchondral bone changes in OA
using a mouse model.
Methods: Osteoarthritis was induced by partial medial menis-
cectomy of the right knee using a microsurgical technique in
C57Bl/6 wild-type (WT) and PAR-2 knock-out (PAR-2 KO) mice.
Knee swelling was measured twice a week for the entire duration
of the study (8 weeks) with a digital calliper. Histological evalua-
tion assessing cartilage structure, cellularity, matrix staining and
remodelling in the deep zone (global score corresponding to the
sum of the different criteria), as well as morphometric evaluation of
the subchondral bone were performed at 4 and 8 weeks and val-
ues compared to control. A comparison between WT (n=9-10 per
group) and PAR-2 KO (n=5-9 per group) mice was also performed.
Results: Knee swelling was observed in the WT immediately fol-
lowing surgery and increased with time (until week 8). The knee
swelling of the PAR-2 KO mice was signiﬁcantly lower (p<0.0001)
at both 4 and 8 weeks post-surgery than the WT group. Both WT
and PAR-2 KO mice demonstrated cartilage damage at 4 and 8
weeks post-surgery; however, lesions were less severe in the PAR-
2 KO mice (p<0.03 on the global score). More speciﬁcally, com-
pared to PAR-2 KO mice, WT mice had more severe alterations of
the cartilage structure at 4 and 8 weeks post-surgery (p<0.0001
and p<0.02, respectively), a higher hypocellularity (p<0.003), and
a signiﬁcant loss of cartilage (p<0.04) as shown by cartilage thick-
ness measurement. Yet, no signiﬁcant differences in the structural
changes in the deep zone of cartilage and in the subchondral
bone were found in either WT or PAR-2 KO mice. However, con-
trol (unoperated) PAR-2 KO mice had less bone surface than the
autologous WT mice (p<0.04).
Conclusions: This study is the ﬁrst to demonstrate the in vivo
implication of PAR-2 in the development of experimental OA,
thus conﬁrming its involvement in OA structural changes. It also
showed that PAR-2 plays a role on subchondral bone that needs
to be further explored. Consequently, these ﬁndings reinforce the
therapeutic potential of a PAR-2 antagonist for the treatment of OA.
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Purpose: Synovitis (as deﬁned by hypertrophy and effusion) is
common in osteoarthritis and may be important in both pain
and structural progression. In addition, chondroitin sulphate (CS)
treatment has been associated with a signiﬁcant decrease in
the incidence of joint swelling, effusion or both. The aim of this
study was to assess the efﬁcacy of CS alone or in combination
with glucosamine sulfate (GS) on synovitis in patients with knee
osteoarthritis (KOA).
Methods: Retrospective study involving 115 outpatients with syn-
ovitis who received CS 800 mg (N=36) (Condrosan®, Bioibérica
S.A., Barcelona), CS 800 mg + SG 1500 mg (N=41) (Cartisorb®,
Bioibérica S.A., Barcelona) or acetaminophen (ACET) 500 mg
(N= 38) for their KOA on a daily basis for a 6-month period.
Synovitis was measured in the suprapatellar recess using ultra-
sonography (US) equipment with a high frequency linear array.
The maximal synovial thickness and effusion depth were mea-
sured in millimeters using the longitudinal axis. Synovitis was
deﬁned as present in measures ≥4 mm. Furthermore, knee pain
according to Huskisson’s VAS, extra acetaminophen consumption
and the presence of meniscal extrusion and Baker’s cyst were
also assessed. Patient’s follow-up was performed after 1, 2, 3 and
6 months of treatment.
Results: From the 115 included subjects, 111 (96,5%) were
female, had a mean age (SD) of 62,4 (10,8) years, mean BMI
(SD) of 27,4 (4,5) kg/m2, 20 (17,4%) presented Baker’s cyst and
13 (11,3%) meniscal extrusion. The mean synovitis (SD) was 6,3
(1,3) mm and the mean knee pain (SD) was 6,5 (1,8) mm. Patients
in all groups had similar baseline characteristics.
Among all the included subjects, a positive correlation between
BMI and the size of synovitis (r=0,138; p=0,002) and knee pain
(r=0,136; p=0,003) was noted. In addition, a positive correlation
between synovitis and knee pain (r=0,385; p=0,000) was also
detected.
Regarding US assessments, the three treatment groups experi-
enced a decrease in synovitis over time. However, patients treated
with SYSADOAs reached physiological mean values after the
second month of treatment. This improvement in synovitis was
maintained in the course of treatment with a mean synovitis (SD)
of 3,2 (2,7) mm in the CS group and of 2,9 (2,6) mm in the
CS+SG group after 6 months of treatment. Multiple comparisons
between groups, showed a signiﬁcant decrease in synovitis after
SYSADOA therapy vs ACET treatment after the ﬁrst month of
follow-up.Statistical analysis demonstrated a faster decrease in
knee pain with CS vs ACET (p= 0,000) and in the CS + SG
group vs ACET (p=0,000). Analysis at each visit for the decrease
in pain scores showed that the differences between CS+ SG vs
ACET were signiﬁcant after the ﬁrst month of treatment (p=0,037)
and between CS vs ACET after the second month of treatment
(p=0,017).
